Wegovy vs Mounjaro: Head-to-Head Efficacy Comparison

How Wegovy and Mounjaro Work Differently

Wegovy and Mounjaro both belong to the incretin-based drug class, but they activate different receptor targets. That distinction drives their divergent efficacy profiles and explains why one consistently produces more weight loss than the other in clinical trials.

Wegovy: A Pure GLP-1 Receptor Agonist

Wegovy contains semaglutide at a 2.4 mg weekly dose. It binds exclusively to the glucagon-like peptide-1 (GLP-1) receptor, slowing gastric emptying, reducing appetite, and enhancing glucose-dependent insulin secretion [1]. The FDA approved Wegovy in June 2021 for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [2].

Mounjaro: A Dual GIP/GLP-1 Receptor Agonist

Mounjaro contains tirzepatide, which activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. GIP receptor activation appears to amplify the metabolic effects of GLP-1 signaling, including enhanced fat oxidation, improved insulin sensitivity, and a potentially stronger satiety signal [3]. The FDA approved Mounjaro in May 2022 for type 2 diabetes. Its obesity-indication counterpart, Zepbound (same molecule, same manufacturer), received FDA approval in November 2023 for chronic weight management [4].

The dual-agonist mechanism is not a minor pharmacological footnote. It is the most likely explanation for tirzepatide's consistent weight-loss superiority across every comparative dataset available.

The First Direct Head-to-Head Trial: SURMOUNT-5

Until late 2024, clinicians had to compare Wegovy and Mounjaro using cross-trial analysis, an inherently imprecise exercise. SURMOUNT-5 changed that. This was the first randomized, double-blind trial directly comparing tirzepatide and semaglutide 2.4 mg at their maximum approved doses for obesity [5].

Trial Design and Population

SURMOUNT-5 enrolled 751 adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, excluding type 2 diabetes. Participants were randomized to tirzepatide (escalated to a maximum of 15 mg weekly) or semaglutide 2.4 mg weekly for 72 weeks [5].

Primary Efficacy Results

Tirzepatide produced 20.2% mean body-weight loss from baseline compared with 13.7% for semaglutide, a difference of 6.5 percentage points (P<0.001) [5]. The percentage of participants achieving at least 10% weight loss was 85.7% with tirzepatide versus 73.2% with semaglutide. For the clinically meaningful threshold of ≥20% weight loss, 51.5% of tirzepatide-treated participants reached it compared with 27.0% on semaglutide [5].

These numbers are not subtle. A 6.5-percentage-point gap in mean weight loss, confirmed in a rigorous head-to-head design, represents a real and reproducible difference. As Dr. Ania Jastreboff, one of the trial's lead investigators, noted: "This is the first study to directly compare these two medications at their approved doses for obesity, and the results demonstrate a clear efficacy difference."

What SURMOUNT-5 Does Not Tell Us

The trial excluded patients with type 2 diabetes, so these results apply specifically to obesity without T2D. The trial duration was 72 weeks. Longer-term durability data from direct comparison remain unavailable. Cost, insurance coverage, and individual tolerability may still favor one drug over the other in clinical practice.

Placebo-Controlled Trial Results: Side-by-Side Analysis

Before SURMOUNT-5, the two anchor trials were STEP-1 (for semaglutide) and SURMOUNT-1 (for tirzepatide). While cross-trial comparisons carry limitations, these studies used similar populations and endpoints, making cautious comparison reasonable.

STEP-1: Semaglutide 2.4 mg

STEP-1 randomized 1,961 adults with obesity or overweight (without T2D) to semaglutide 2.4 mg or placebo for 68 weeks. Semaglutide produced 14.9% mean body-weight loss versus 2.4% for placebo [1]. The proportion of patients losing ≥5% body weight was 86.4% with semaglutide versus 31.5% with placebo. About one-third of semaglutide-treated participants lost ≥20% of their body weight [1].

SURMOUNT-1: Tirzepatide 5, 10, and 15 mg

SURMOUNT-1 randomized 2,539 adults with obesity or overweight (without T2D) to tirzepatide at 5 mg, 10 mg, or 15 mg, or placebo for 72 weeks. Mean weight loss was 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg), compared with 3.1% for placebo [6]. At the highest dose, 36.2% of participants achieved ≥25% weight loss [6].

Cross-Trial Perspective

The difference between semaglutide's 14.9% at 68 weeks and tirzepatide's 20.9% at 72 weeks suggested a roughly 6-percentage-point advantage for tirzepatide. SURMOUNT-5 confirmed this gap with a nearly identical magnitude (6.5 percentage points), lending strong credibility to the cross-trial signal [5].

Efficacy in Patients With Type 2 Diabetes

Weight loss tends to be lower in patients with T2D for both drugs. The metabolic environment of insulin resistance and diabetes medications can blunt the magnitude of weight reduction. Trial data from the STEP and SURPASS programs confirm this pattern.

STEP-2: Semaglutide in T2D

In STEP-2 (N=1,210), semaglutide 2.4 mg produced 9.6% mean weight loss at 68 weeks in adults with T2D and overweight or obesity, compared with 3.4% for placebo [7]. A1C fell by 1.6 percentage points from a baseline of 8.1% [7].

SURPASS-2: Tirzepatide vs Semaglutide 1 mg in T2D

SURPASS-2 (N=1,879) compared tirzepatide 5, 10, and 15 mg against semaglutide 1 mg (not 2.4 mg) in adults with T2D inadequately controlled on metformin alone. A1C reductions were 2.01%, 2.24%, and 2.30% for tirzepatide 5, 10, and 15 mg, versus 1.86% for semaglutide 1 mg [3]. Weight loss was 7.6 kg, 9.3 kg, and 11.2 kg for tirzepatide versus 5.7 kg for semaglutide 1 mg [3].

An Important Caveat

SURPASS-2 compared tirzepatide against semaglutide 1 mg, the diabetes dose, not the 2.4 mg obesity dose. This trial establishes tirzepatide's superiority over a lower semaglutide dose for glycemic control and weight loss in T2D, but it does not directly address the Wegovy-dose comparison in diabetic patients. The SURMOUNT-2 trial (tirzepatide for obesity in T2D, N=938) showed 12.8% to 14.7% weight loss at 72 weeks with tirzepatide versus 3.2% for placebo [8]. No head-to-head trial of tirzepatide versus semaglutide 2.4 mg in T2D populations has been published.

Cardiovascular and Metabolic Outcomes Beyond Weight

Weight loss alone does not capture the full clinical picture. Both drugs affect cardiometabolic risk markers, but the evidence base for cardiovascular outcomes differs substantially between them.

SELECT: Semaglutide's Cardiovascular Proof

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% compared with placebo in adults with overweight or obesity and established cardiovascular disease, but without diabetes [9]. This was a landmark result. It established semaglutide as the first obesity medication with proven cardiovascular risk reduction [9].

Tirzepatide's Cardiovascular Data Gap

Tirzepatide does not yet have a completed cardiovascular outcomes trial. The SURPASS-CVOT study is ongoing. Pre-specified secondary analyses from SURMOUNT and SURPASS trials have shown favorable trends in blood pressure, triglycerides, and inflammatory markers [6], but these are not substitutes for a dedicated CVOT.

Metabolic Markers

Both drugs improve fasting glucose, insulin sensitivity, triglycerides, and blood pressure. In SURMOUNT-5, tirzepatide showed greater reductions in waist circumference (19.4 cm vs 14.4 cm) compared with semaglutide, consistent with its larger overall weight effect [5]. Reductions in systolic blood pressure were similar between the two arms.

For patients whose primary treatment goal includes cardiovascular risk reduction, semaglutide currently has the stronger evidence base. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity notes the SELECT trial as a consideration when selecting among GLP-1 receptor agonists [10].

Side Effects and Tolerability

Gastrointestinal (GI) side effects are the most common adverse events with both Wegovy and Mounjaro, driven by their shared GLP-1 receptor activity. The safety profiles are more similar than different.

GI Side Effects in SURMOUNT-5

In the head-to-head trial, nausea occurred in 28.4% of tirzepatide-treated patients versus 23.6% for semaglutide. Diarrhea rates were 21.8% for tirzepatide and 16.4% for semaglutide. Vomiting was 17.9% versus 13.4% [5]. Most GI events were mild to moderate in severity and concentrated during the dose-escalation phase.

Discontinuation Rates

Treatment discontinuation due to adverse events was 4.3% for tirzepatide and 2.9% for semaglutide in SURMOUNT-5 [5]. In STEP-1, 7.0% of semaglutide-treated patients discontinued for adverse events [1]. In SURMOUNT-1, discontinuation rates for adverse events ranged from 4.3% to 7.1% across tirzepatide dose groups [6]. These differences are small and not statistically powered for comparison.

Serious Adverse Events

Rates of pancreatitis, gallbladder events, and thyroid C-cell concerns remain low with both agents. Both carry boxed warnings about medullary thyroid carcinoma risk based on rodent studies, though no confirmed causal link exists in humans [2][4]. Ongoing pharmacovigilance data have not identified new safety signals for either drug.

Choosing Between Wegovy and Mounjaro

The clinical decision depends on more than peak weight-loss numbers. Individual patient factors, insurance coverage, comorbidities, and treatment goals all shape which drug is the better fit.

When Tirzepatide (Mounjaro/Zepbound) May Be Preferred

Patients who prioritize maximum weight loss may benefit from tirzepatide's consistently larger effect size. Those with T2D seeking simultaneous glycemic control and weight management also have strong evidence supporting tirzepatide, based on the SURPASS program [3]. If a patient has had a partial response to semaglutide (weight loss plateauing below goal), switching to tirzepatide is a reasonable clinical strategy, supported indirectly by the SURMOUNT-5 efficacy differential [5].

When Semaglutide (Wegovy) May Be Preferred

Patients with established cardiovascular disease and obesity have the strongest evidence base with semaglutide, given the SELECT trial's 20% MACE reduction [9]. For formulary or cost reasons, semaglutide may be more accessible in certain insurance plans. Patients who tolerate semaglutide well and achieve satisfactory weight loss have no clinical reason to switch.

Practical Considerations

Both drugs require once-weekly subcutaneous injection. Both use auto-injector pen devices. Dose titration schedules differ: Wegovy escalates over 16 weeks to the 2.4 mg maintenance dose [2], while Mounjaro escalates in 2.5 mg increments every four weeks, with the option to remain at 5, 10, or 15 mg based on response and tolerability [4]. Supply shortages have affected both medications intermittently, and availability should be confirmed at the time of prescribing.

Patients beginning treatment should expect GI side effects during titration regardless of which drug they choose. Slow dose escalation, small meal sizes, and adequate hydration reduce the severity of nausea in most cases. If a patient cannot tolerate semaglutide 2.4 mg, tirzepatide is not guaranteed to be tolerated either, since GLP-1 receptor activation drives the majority of GI effects in both drugs.